Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RVU120
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Ryvu Therapeutics
Deal Size : $1.0 million
Deal Type : Agreement
Details : RVU120 is a selective, first-in-class dual CDK8/CDK19 kinase inhibitor that has shown signs of clinical activity in treated patients, as well as efficacy in numerous in vitro and in vivo models of hematologic malignancies and solid tumors.
Product Name : RVU120
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 07, 2023
Lead Product(s) : RVU120
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Ryvu Therapeutics
Deal Size : $1.0 million
Deal Type : Agreement
Lead Product(s) : PKL-021
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Pikralida biopharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Polpharma Partners with Pikralida Biopharmaceutical Start-Up
Details : The partnership involves manufacturing of the drug substance of the clinical candidate PKL-021, needed to support the preclinical research program and the production of an investigational medicinal product for the phase one clinical trial.
Product Name : PKL-021
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 19, 2022
Lead Product(s) : PKL-021
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Pikralida biopharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
KEY PRODUCTS
Reset All
Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.
